Last reviewed · How we verify

Ropivacaine 0.4%

University of California, San Diego · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameRopivacaine 0.4%
Also known ascontinuous peripheral nerve block
SponsorUniversity of California, San Diego
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and action potential propagation. This results in a loss of sensation in the area where it is administered. It is an amide-type local anesthetic with a long duration of action and lower cardiotoxicity compared to some other local anesthetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: